Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Connect Biopharma Holdings (CNTB) Operating Leases (2023 - 2025)

Connect Biopharma Holdings' Operating Leases history spans 3 years, with the latest figure at $445000.0 for Q3 2025.

  • For Q3 2025, Operating Leases changed N/A year-over-year to $445000.0; the TTM value through Sep 2025 reached $445000.0, changed N/A, while the annual FY2024 figure was $24000.0, 86.67% down from the prior year.
  • Operating Leases for Q3 2025 was $445000.0 at Connect Biopharma Holdings, down from $870000.0 in the prior quarter.
  • Across five years, Operating Leases topped out at $870000.0 in Q2 2025 and bottomed at $24000.0 in Q4 2024.
  • The 3-year median for Operating Leases is $445000.0 (2025), against an average of $422600.0.
  • The largest YoY upside for Operating Leases was 86.67% in 2024 against a maximum downside of 86.67% in 2024.
  • A 3-year view of Operating Leases shows it stood at $180000.0 in 2023, then tumbled by 86.67% to $24000.0 in 2024, then surged by 1754.17% to $445000.0 in 2025.
  • Per Business Quant, the three most recent readings for CNTB's Operating Leases are $445000.0 (Q3 2025), $870000.0 (Q2 2025), and $594000.0 (Q1 2025).